Stockhub

Cantabio Pharmaceuticals, Inc.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

2 September 2022

  • curprev 05:0405:04, 2 September 2022 95.149.241.133 talk 997 bytes +997 Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Cantabio Pharmaceuticals, Inc., a preclinical stage biotechnology company, focuses on the research, development, and commercialization of novel therapies for Parkinson's disease (PD), Alzheimer's disease (AD), and other related diseases. Its lead programs include CB101, a DJ-1 targeting small molecule pharmacological chaperone for use in the treatment of PD; CB201, a CNS penetrant engineered DJ-1 protein for use in the trea..."
Retrieved from "https://stockhub.co/research/Cantabio_Pharmaceuticals,_Inc."